Trial Profile
A longitudinal prospective study assessing efficiency and the safety of Peginterferon-alfa-2b used for the treatment of hepatitis C infection in patients undergoing hemodialysis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Mar 2016
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 04 Mar 2016 New trial record